RCM
STLNW

Radcliffe Capital Management’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

Radcliffe Capital Management’s Portfolio STLNW Stock Details STLNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20,000
Closed -$199K – 1068
2021
Q3 		$199K Sell
20,000
-42,500
-68% -$58.6K 0.01% 874
2021
Q2 		$622K Hold
62,500
– – 0.02% 831
2021
Q1 		$623K Buy
+62,500
New +$116K 0.02% 630

Other funds holding STLNW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
DCM
Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return
USPCM
Union Square Park Capital Management New York $176M AUM 51.52% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Radcliffe Capital Management's STLNW Position: Q4 2021 in Review

Radcliffe Capital Management sold out of Starling Oncology, Inc. Warrant (STLNW) in Q4 2021, closing a stake of 20,000 shares — an estimated $199K sold.

Radcliffe Capital Management first reported a position in STLNW in Q1 2021 and held it in 3 quarters. The position peaked at $623K in Q1 2021. 20 funds tracked by Wall St. Rank hold STLNW as of Q4 2021.

  • Radcliffe Capital Management reported no remaining Starling Oncology, Inc. Warrant position as of Q4 2021 after selling out during the quarter.
  • Radcliffe Capital Management sold 20,000 Starling Oncology, Inc. Warrant shares in Q4 2021, an estimated $199K.
  • Radcliffe Capital Management first reported a position in Starling Oncology, Inc. Warrant in Q1 2021 and held it in 3 quarters.
  • Radcliffe Capital Management's Starling Oncology, Inc. Warrant position peaked at $623K in Q1 2021.
  • 20 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q4 2021.

Based on Radcliffe Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.